Search Results - "WIRAPATI, P"

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial by Mooi, J.K., Wirapati, P., Asher, R., Lee, C.K., Savas, P., Price, T.J., Townsend, A., Hardingham, J., Buchanan, D., Williams, D., Tejpar, S., Mariadason, J.M., Tebbutt, N.C.

“…The consensus molecular subtypes (CMS) is a transcriptome-based classification of colorectal cancer (CRC) initially described in early-stage cohorts, but the…”
Get full text

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial by Stintzing, S., Wirapati, P., Lenz, H.-J., Neureiter, D., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Moehler, M., Scheithauer, W., Held, S., Modest, D.P., Jung, A., Kirchner, T., Aderka, D., Tejpar, S., Heinemann, V.

“…FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients…”
Get full text

Aflibercept efficacy according to sidedness, RAS and BRAF mutations. Findings from the VELOUR trial in second line therapy of advanced colorectal cancer patients by Maiello, E., Pomella, V., Wirapati, P., Di Bartolomeo, M., Zampino, M.G., Leone, F., Latiano, T.P., Pietrantonio, F., Ravenda, P.S., Marino, D., Tejpar, S.

Get full text

223 A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer by Iggo, R, Farmer, P, Wirapati, P, Anderle, P, Delorenzi, M, Bogaerts, J, Piccart, M, Cameron, D, Bergh, J, Bonnefoi, H

Get full text

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer by Delorenzi, Mauro, Farmer, Pierre, Bonnefoi, Hervé, Anderle, Pascale, Cameron, David, Wirapati, Pratyakasha, Becette, Véronique, André, Sylvie, Piccart, Martine, Campone, Mario, Brain, Etienne, MacGrogan, Gaëtan, Petit, Thierry, Jassem, Jacek, Bibeau, Frédéric, Blot, Emmanuel, Bogaerts, Jan, Aguet, Michel, Bergh, Jonas, Iggo, Richard

“…Identifying factors that influence response to cancer chemotherapy is crucial for improving its efficacy. Mauro Delorenzi and his colleagues report that a…”
Get full text

Meiotic breakpoint mapping of a proposed X linked visual loss susceptibility locus in Leber's hereditary optic neuropathy by Handoko, H Y, Wirapati, P J, Sudoyo, H A, Sitepu, M, Marzuki, S

“…Leber's hereditary optic neuropathy (LHON) is a maternally inherited degenerative disorder characterised by an acute or subacute optic nerve degeneration…”
Get full text

Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis by Sotiriou, Christos, Wirapati, Pratyaksha, Loi, Sherene, Harris, Adrian, Fox, Steve, Smeds, Johanna, Nordgren, Hans, Farmer, Pierre, Praz, Viviane, Haibe-Kains, Benjamin, Desmedt, Christine, Larsimont, Denis, Cardoso, Fatima, Peterse, Hans, Nuyten, Dimitry, Buyse, Marc, Van de Vijver, Marc J., Bergh, Jonas, Piccart, Martine, Delorenzi, Mauro

“…Background: Histologic grade in breast cancer provides clinically important prognostic information. However, 30%–60% of tumors are classified as histologic…”
Get full text

Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial by Mooi, J., Wirapati, P., Asher, R., Lee, C., Savas, P., Price, T.J., Tejpar, S., Mariadason, J., Tebbutt, N.

Get full text

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial by Stintzing, S, Wirapati, P, Lenz, H-J, Neureiter, D, Fischer von Weikersthal, L, Decker, T, Kiani, A, Kaiser, F, Al-Batran, S, Heintges, T, Lerchenmüller, C, Kahl, C, Seipelt, G, Kullmann, F, Moehler, M, Scheithauer, W, Held, S, Modest, D P, Jung, A, Kirchner, T, Aderka, D, Tejpar, S, Heinemann, V

“…FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients…”
Get full text

Chromosomal number aberrations and transformation in adult mouse retinal stem cells in vitro by DJOJOSUBROTO, M, BOLLOTTE, F, WIRAPATI, P, RADTKE, F, STAMENKOVIC, I, ARSENIJEVIC, Y

“…Purpose The therapeutic potential of stem cells on degenerative diseases and damaged tissues such as retinal degeneration has been recognized. Generation of…”
Get full text

Biological mechanisms that trigger breast cancer (BC) tumor progression are molecular subtype dependent by Sotiriou, C., Desmedt, C., Haibe-Kains, B., Harris, A., Larsimont, D., Buyse, M., Wirapati, P., Delorenzi, M., Bontempi, G., Piccart, M.

“…Abstract only 10581 Background: We have recently developed several gene expression indices related to hallmarks of breast cancer involving various biological…”
Get full text

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer by Farmer, P, Bonnefoi, H, Anderle, P, Cameron, D, Wirapati, P, Becette, V, Andre, S, Piccart, M, Campone, M, Brain, E, MacGrogan, G, Petit, T, Jassem, J, Bibeau, F, Blot, E, Bogaerts, J, Aguet, M, Bergh, J, Iggo, R, Delorenzi, M

Get full text

Different prediction of distant recurrence risk in primary breast cancer patients stratified by ER and ERBB2 status by Urban, P., Vuaroqueaux, V., Labuhn, M., Delorenzi, M., Wirapati, P., Dieterich, H., Ehret, S., Fürstenberger, G., Morant, R., Eppenberger, U., Eppenberger-Castori, S.

“…Abstract only 20120 Background: Molecular profiling recently defined biological characteristics of several long-recognized breast cancer subtypes including…”
Get full text

Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC) by Sotiriou, C., Wirapati, P., Loi, S., Haibe-Kains, B., Desmedt, C., Tutt, A., Ellis, P., Buyse, M., Delorenzi, M., Piccart, M.

“…Abstract only 507 Background: Although, the development of high-throughput gene expression technologies has allowed the identification of several “molecular…”
Get full text

Molecular characterization of clinical grade in breast cancer (BC) challenges the existence of “grade 2” tumors by Sotiriou, C., Wirapati, P., Loi, S., Desmedt, C., Harris, A. L., Bergh, J., Smeds, J., Cardoso, F., Delorenzi, M., Piccart, M.

“…Abstract only…”
Get full text

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer by Iggo, R, Farmer, P, Wirapati, P, Anderle, P, Delorenzi, M, Bogaerts, J, Piccart, M, Cameron, D, Bergh, J, Bonnefoi, H

Get full text

Gene expression profiling in breast cancer challenges the existence of intermediate histological grade by Sotiriou, C, Wirapati, P, Loi, S, Harris, A, Bergh, J, Smeds, J, Praz, V, Farmer, P, Haibe-Kains, B, Lallemand, F, Buyse, M, Piccart, M, Delorenzi, M

Get full text

Is genomic grading killing histological grading? by Sotiriou, C., Wirapati, P., Loi, S., Desmedt, C., Haibe-Kains, B., Piette, F., Buyse, M., Bontempi, G., Delorenzi, M., Piccart, M.

Get full text

A stroma-related gene signature predicts resistance to epirubicin-containing neoadjuvant chemotherapy in breast cancer by Farmer, P, Bonnefoi, H, Anderle, P, Cameron, D, Wirapati, P, Becatte, V, Andre, S, Piccart, M, Campone, M, Tabiana-Hulin, M, MacGrogan, G, Petit, T, Jassem, J, Rouanet, P, Blot, E, Bogaerts, J, Bergh, J, Iggc, R, Delorenzi, M

Get full text

Molecular characterization of clinical grade in breast cancer (BC) challenges the existence of "grade 2" tumors by Sotiriou, C, Wirapati, P, Loi, S, Desmedt, C, Harris, AL, Bergh, J, Smeds, J, Cardoso, F, Delorenzi, M, Piccart, M

Get full text